GHRP-6 Acetate 5 mg Dosage Protocol
Table of Contents
What is GHRP-6 Acetate?
GHRP-6 (Growth Hormone-Releasing Peptide 6) Acetate is a synthetic hexapeptide that acts as a potent, selective growth hormone secretagogue (GHS). It functions primarily as a ghrelin mimetic, binding directly to the growth hormone secretagogue receptor (GHS-R1a) located in the anterior pituitary gland and the hypothalamus. This binding triggers an acute, pulsatile release of endogenous growth hormone (GH) while simultaneously counteracting the inhibitory actions of somatostatin.
Potential Areas of Research
- Pulsatile GH Stimulation: Extensively studied for its capability to prompt sharp, natural pulses of growth hormone, resulting in downstream elevations of IGF-1.
- Appetite Modulation: Evaluated in metabolic and cachexia models due to its strong orexigenic (appetite-stimulating) properties driven by ghrelin receptor activation.
- Cytoprotection & Tissue Repair: Profiled in preclinical wound-healing and organ models for its ability to reduce scar formation, protect cardiac tissue, and offer neuroprotection.
- Body Composition: Investigated for its role in altering cellular pathways linked to lean mass development and fat oxidation.
GHRP-6 Acetate 5 mg Dosage Protocol
- Vial Size: 5 mg
- Reconstitution: 3.0 mL Bacteriostatic Water
- Concentration: ~1.67 mg/mL (16.7 mcg per Syringe Unit)
- Administration: Subcutaneous Injection
- Frequency: 3 times daily, spaced at least 4 hours apart (typically morning, midday, and bedtime)
Dosage Chart
Phase
Dose per Injection
Syringe Units (100-Unit / 1mL Syringe)
Weeks 1–2 (Titration)
100 mcg
6 Units
Weeks 3–4 (Intermediate)
200 mcg
12 Units
Weeks 5–12 (Target)
300 mcg
18 Units
Protocol Note: GHRP-6 Acetate exhibits a short half-life of approximately 2.5 hours, necessitating multiple daily applications rather than a single large dose. To maximize the growth hormone pulse, injections must be administered on an empty stomach—ideally 2 to 3 hours after a meal, and at least 30 minutes before any subsequent food intake.
Reconstitution
- Allow the lyophilized 5 mg vial to adjust to room temperature prior to mixing to avoid moisture contamination.
- Draw 3.0 mL of sterile bacteriostatic water and slowly inject it into the vial.
- Aim the needle at the inner glass wall of the vial, letting the diluent flow down gently to eliminate foaming.
- Softly swirl or roll the vial between your palms until the powder is fully dissolved. Do not shake the vial.
- Verify the appearance of the solution post-reconstitution; it must be completely transparent and clear. Discard immediately if any floating particles or cloudiness appear.
Storage
- Before reconstitution: Store frozen at −20°C (−4°F) for optimal long-term structural integrity. Keep protected from light in a dry environment.
- After reconstitution: Store refrigerated at 2–8°C (35.6–46.4°F) and protect from UV light exposure.
- Important: Reconstituted GHRP-6 Acetate is highly sensitive and must be used within 7 days. Do not freeze the solution after reconstitution, and avoid all unnecessary structural agitation.
Injection & Handling Technique
To preserve experimental accuracy and minimize localized tissue reactions in laboratory models, observe standard subcutaneous handling:
- Site Selection: Administer via subcutaneous injection into the adipose layer of the abdomen (maintaining a 2-inch radius from the navel), outer thighs, or the back of the upper arms.
- Systematic Site Rotation: Systematically alternate the targeted injection coordinates daily to mitigate local skin irritation, bruising, or the development of lipohypertrophy.
- Administration Speed: Depress the syringe plunger slowly and steadily over 5 seconds. Hold the needle in place for an additional 2 to 3 seconds before withdrawing to prevent solution backflow.
Technical Research Note
Because GHRP-6 Acetate actively mimics endogenous ghrelin, it frequently induces a rapid, profound increase in appetite shortly after administration, which should be accounted for in metabolic tracking models. Researchers should also note that acute GHS-R1a activation can cause transient, mild elevations in cortisol and adrenocorticotropic hormone (ACTH), as well as short-lived flushing or mild fluid retention. These elevations generally remain within normal physiological ranges and normalize rapidly. Due to the downstream signaling of the GH/IGF-1 axis, this compound is contraindicated in research models with active malignant neoplasms.
Regulatory Compliance Disclaimer
IMPORTANT NOTICE: This product is engineered and distributed exclusively for in-vitro laboratory testing and scientific research applications. It is strictly NOT a medicine, drug, or dietary supplement and is not intended for human consumption or veterinary use. This compound has not been evaluated or approved by the MHRA, FDA, or EMA. Any use outside of legitimate, controlled laboratory environments is strictly prohibited. The purchaser assumes all liability for the safe handling and legal compliance of this material.
View Supplier
References
- CDC (2024)
— Safe Injection Practices: Core Principles for Reducing Injection-Related Risks
- Clinical Medicine Insights: Cardiology (2017)
— Mechanism of Action of GHRP-6: Ghrelin Receptor Activation and Appetite-Stimulating Effects
- International Wound Journal (2018)
— GHRP-6 prevents cutaneous hypertrophic scarring: proteome study
- Sexual Medicine Reviews (2018)
— Growth Hormone Secretagogues: Effects on Body Composition, Lean Mass, and Fat Loss
- Sexual Medicine Reviews (2018)
— Clinical Safety and Tolerability of Growth Hormone Secretagogues in Human Studies
- Clinical Diabetes (2019)
— Optimizing Injection Technique: Why Proper Administration Practices Matter